Recurrence of dermatophytosis and therapeutic efficacy of systemic antifungals in recurrent dermatophytosis of adults– A randomized, assessor-blind controlled trial in a tertiary institution
Use of systemic antifungals in recurrent dermatophytosis: A randomized, controlled trial.
Keywords:Recurrent, Dermatophytosis, Itraconazole, Terbinafine, Randomized controlled trial
AbstractBackground- Dermatophytosis is becoming difficult to treat in India by traditional treatment regime for its frequent relapse or recurrence. Objective- To validate the efficacy and safety of supra-pharmacological dose of Itraconazole in one arm and combination of Itraconazole and Terbinafine in another arm for successful treatment of recurrent dermatophytosis. Methods- The study was a single-center, randomized, assessor-blind, parallel-group, multi-arm, controlled trial on 155 patients with allocation ratio as 1:1:1. The control group (Group A) received conventional dose of oral Itraconazole and two experimental groups received supra-pharmacological dose of oral Itraconazole (400 mg for 2 weeks and 200 mg for another 2 weeks for Group B) and combination of oral Itraconazole (200 mg for 4 weeks) and Terbinafine (250 mg for 4 weeks in Group C) respectively. The clinical and mycological cure was noticed in every group. Statistical analysis was done with the help of Microsoft Excel and Med Calc 12 software. Results- 41, 42 and 41 patients of respective three groups were completed their last follow-up visits. 78.57% and 73.18% of patients showed cure in Group B and C respectively whereas 4.88% cure in control group. So, both the experimental groups show better outcome compared to the conventional treatment (p<0.001). In the multiple regression model, it is clearly shown that the clinico-mycological cure is dependent on the treatment regime (p = <0.0001), not on the fungal species (p = 0.0622). Limitations- Small sample size and single-centre study were some limitations. Conclusion-Supra-pharmacological dose of oral Itraconazole or a combination of Itraconazole and Terbinafine can be given in recurrent tinea cases.
(1) Naglot A, Shrimati DD, Nath BK, Gogoi HK, Veer V et al. Recent trends of Dermatophytosis in Northeast India (Assam) and interpretation with published studies. Int CurrMicrobiol App Sci. 2015;4(11):111-120.
(2) Dogra S, Uprety S. The menace of chronic and recurrent Dermatophytosis in India: Is the problem deeper than we perceive? Indian Dermatol Online J 2016;7:73-6.
(3) Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris and tinea pedis: A comprehensive review. Indian Dermatol Online J 2016;7:77-86.
(4) Dogra S, Narang T. Emerging atypical and unusual presentations of dermatophytosis in India. Clin Dermatol Rev. 2017;1:12-18.
(5) Sentamilselvi G. Dermatophytosis. In:Sentamilselvi G, Janaki VR, Janaki C, editors. The handbook of Dermatomycology and colour atlas. 1st ed. India: Dr. G. Sentamilselvi; 2006. p. 9-15.
(6) Gupta AK, Foley KA. Systemic antifungal Agents. In:Wolverton SE, editor. Comprehensive dermatologic drug therapy. 4th ed. India: Elsevier Saunders; 2021. p.99-113.
(7) Boonk W, de Geer D, de Kreek E, Remme J, van HuysteeB. Itraconazole in the treatment of tineacorporis and tineacruris: comparision of two treatment schedules. Mycoses. 1998 Dec;41(11-12):509-14.
(8) Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K et al. Expert consensus on the management of Dermatophytosis in India (ECTODERM India). BMC Dermatol /18, 6 (2018).
(9) Rengassamy M, Chellam J, Ganapati S. Systemic therapy of dermatophytosis: Practical and systemic approach. Clin Dermatol Rev 2017;1, Suppl S1:19-23.
(10) Ellis D, Watson A. Systemic antifungal agents for cutaneous fungal infections. AustPrescr1996;19:72-5.
(11) Thursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD, et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008;38:496-520.
(12) Mrig PA, Sardana K. Rationale of use of Antifungal Drugs Based on Skin Pharmacokinetics. In: Sardana K, Khurana A, Garg S, Poojary S, editors. IADVL Manual on Management of Dermatophytoses. 1st ed. India: CBS Publishers & Distributors Pvt Ltd; 2018. p. 65-72.
(13) Pierard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum. A comparative study. J Am Acad Dermatol 1995;32:429-35.
(14) Saunte D, Pereiro-Ferreirós M, Rodríguez-Cerdeira C, Sergeev A, Arabatzis M, Prohić A, et al. Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic. J Eur Acad Dermatol Venereol. 2021 March;35:1582-1586.
(15) Jabet A, Brun S, Normand A, Imbert S, Akhoundi M, Dannaoui E, et al. Extensive Dermatophytosis Caused by Terbinafine-Resistant Trichophyton indotineae. Emerg Infect Dis. 2022;28(1):229-233.
(16) Edriss MT, Parker JL, Pritchett, EN. Response to Gu et al’s “Treatment-resistant dermatophytosis: A representative case highlighting an emerging public health threat”. 2022 Jan.
(17) Das S, De A, Saha R, Sharma N, Khemka M, Singh S, et al. The current Indian epidemic of dermatophytosis: A study on causative agents and sensitivity patterns. Indian J Dermatol 2020;65:118-22.